External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Biocon Limited is an innovation-led, global biopharmaceutical company dedicated to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.</li><li>The company has developed and commercialized novel biologics, biosimilars, complex small molecule APIs in India and key global markets, and generic formulations in the US and Europe.</li><li>Additionally, it has a pipeline of promising novel assets in immunotherapy under development.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Limited is an innovation-led, global biopharmaceutical company dedicated to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.The company has developed and commercialized novel biologics, biosimilars, complex small molecule APIs in India and key global markets, and generic formulations in the US and Europe.Additionally, it has a pipeline of promising novel assets in immunotherapy under development.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Biocon - 29th November, 2025

<ul><li>Operational Performance: Biocon reported an in-line performance for Q2FY26, with revenue rising 19.6% YoY and 9% QoQ to Rs 4,296 Cr, driven by strong traction in biosimilars (up 24.7% YoY) and generics (up 24.7% YoY).</li><li>Growth in biosimilars was led by the successful launch and market traction of bUstekinumab, bAspart, bBevacizumab, and bAflibercept across key markets.</li><li>CRDMO Business Update: The CRDMO (Syngene) business posted muted growth, as expected, while continuing to expand its global footprint and capability set.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Operational Performance: Biocon reported an in-line performance for Q2FY26, with revenue rising 19.6% YoY and 9% QoQ to Rs 4,296 Cr, driven by strong traction in biosimilars (up 24.7% YoY) and generics (up 24.7% YoY).Growth in biosimilars was led by the successful launch and market traction of bUstekinumab, bAspart, bBevacizumab, and bAflibercept across key markets.CRDMO Business Update: The CRDMO (Syngene) business posted muted growth, as expected, while continuing to expand its global footprint and capability set.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth

<ul><li>Biocon’s Q1FY26 performance came in below expectations. Revenue grew 14.8% YoY but declined 10.8% QoQ, driven by market share gains for Fulphila and Ogivri, along with the recent launch of Stelara.</li><li>The biosimilars segment grew 18% YoY, while Syngene (Research Services) posted a 10.7% YoY increase.</li><li>Gross margins contracted by 120bps YoY and 230bps QoQ to 64.4%, impacted by the Gx business.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon’s Q1FY26 performance came in below expectations. Revenue grew 14.8% YoY but declined 10.8% QoQ, driven by market share gains for Fulphila and Ogivri, along with the recent launch of Stelara.The biosimilars segment grew 18% YoY, while Syngene (Research Services) posted a 10.7% YoY increase.Gross margins contracted by 120bps YoY and 230bps QoQ to 64.4%, impacted by the Gx business.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>Biocon's Q4FY25 results surpassed expectations.</li><li>Revenue grew 12.8% YoY and 15.6% QoQ, primarily driven by gRevlimid values in the generics segment and the launch of GLP1 in the UK, while the biosimilars segment grew 4.5% YoY. Syngene (Research Services) reported growth of 11% on a YoY Basis.</li><li>The company’s gross margins improved by 60bps YoY and 220bps QoQ to 66.7%. EBITDA margins improved to 24.4%, up 100bps YoY and 470bps QoQ.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon's Q4FY25 results surpassed expectations.Revenue grew 12.8% YoY and 15.6% QoQ, primarily driven by gRevlimid values in the generics segment and the launch of GLP1 in the UK, while the biosimilars segment grew 4.5% YoY. Syngene (Research Services) reported growth of 11% on a YoY Basis.The company’s gross margins improved by 60bps YoY and 220bps QoQ to 66.7%. EBITDA margins improved to 24.4%, up 100bps YoY and 470bps QoQ.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - Growth Driven by Generics; Expansion by New Launches

<ul><li>Biocon Limited is an innovation-led, global biopharmaceutical company dedicated to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.</li><li>The company has developed and commercialised novel biologics, biosimilars, complex small-molecule APIs in India and key global markets, and generic formulations in the US and Europe.</li><li>Additionally, it has a pipeline of promising novel assets in immunotherapy under development.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Limited is an innovation-led, global biopharmaceutical company dedicated to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.The company has developed and commercialised novel biologics, biosimilars, complex small-molecule APIs in India and key global markets, and generic formulations in the US and Europe.Additionally, it has a pipeline of promising novel assets in immunotherapy under development.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Biocon Ltd - 03rd May, 2025

India

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Ltd (BIOS IN)

Pick of the Week: Biocon - 29th November, 2025

The company has developed and commercialized novel biologics, biosimilars, complex small molecule APIs in India and key global markets, and generic...

Axis Direct

Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth

Biocon reported an in-line performance for Q2FY26, with revenue rising 19.6% YoY and 9% QoQ to Rs 4,296 Cr, driven by strong traction in...

Axis Direct

Biocon Ltd - Execution Driving Gains

Biocon’s Q1FY26 performance came in below expectations. Revenue grew 14.8% YoY but declined 10.8% QoQ, driven by market share gains for Fulphila...

Axis Direct

Biocon Ltd - Growth Driven by Generics; Expansion by New Launches

The company’s gross margins improved by 60bps YoY and 220bps QoQ to 66.7%. EBITDA margins improved to 24.4%, up 100bps YoY and 470bps QoQ.

Axis Direct

Pick of the Week: Biocon Ltd - 03rd May, 2025

The company has developed and commercialised novel biologics, biosimilars, complex small-molecule APIs in India and key global markets, and generic...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)